MRK Stock Overview
Merck KGaA operates as a science and technology company in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for MRK from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €169.05 |
| 52 Week High | €202.80 |
| 52 Week Low | €153.10 |
| Beta | 0.62 |
| 1 Month Change | 4.77% |
| 3 Month Change | -2.87% |
| 1 Year Change | -3.95% |
| 3 Year Change | 58.43% |
| 5 Year Change | 102.84% |
| Change since IPO | 990.01% |
Recent News & Updates
These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
Mar 26
MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20
Mar 05Recent updates
These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
Mar 26MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20
Mar 05Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
Feb 14We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt
Dec 12Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?
Nov 09Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?
Aug 15Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?
May 17MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85
Mar 29Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?
Jan 13We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease
Oct 15A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
Sep 19MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Seems To Use Debt Quite Sensibly
Jul 11MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Intrinsic Value Is Potentially 58% Above Its Share Price
Jun 21These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
Apr 03Do Institutions Own MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Shares?
Mar 16Should Weakness in MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Mar 01Can You Imagine How MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Shareholders Feel About The 76% Share Price Increase?
Jan 25Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 07An Intrinsic Calculation For MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Suggests It's 30% Undervalued
Dec 24These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
Dec 11
Is MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Nov 28Shareholder Returns
| MRK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.9% | 2.2% | 1.4% |
| 1Y | -3.9% | -11.5% | -7.2% |
Return vs Industry: MRK exceeded the German Pharmaceuticals industry which returned -10.3% over the past year.
Return vs Market: MRK exceeded the German Market which returned -7.9% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: MRK is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 64,011 | Belen Garijo Lopez | https://www.merckgroup.com |
Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines.
Merck KGaA Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market Cap | €73.50b |
| Earnings (TTM) | €3.24b |
| Revenue (TTM) | €22.33b |
22.7x
P/E Ratio3.3x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | €22.33b |
| Cost of Revenue | €8.48b |
| Gross Profit | €13.85b |
| Other Expenses | €10.60b |
| Earnings | €3.24b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 03, 2023
| Earnings per share (EPS) | 7.46 |
| Gross Margin | 62.01% |
| Net Profit Margin | 14.52% |
| Debt/Equity Ratio | 38.8% |
How did MRK perform over the long term?
See historical performance and comparison